Clinical Trial Update: Obinutuzumab in Treatment of Fibrillary Glomerulonephritis [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating obinutuzumab for fibrillary glomerulonephritis is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fibrillary Glomerulonephritis

Drugs mentioned

• Obinutuzumab (obinutuzumab)

Snippet

Sponsor: Mayo Clinic | Conditions: Fibrillary Glomerulonephritis | Phase 2 | Status: RECRUITING